All Stories

  1. Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease
  2. Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update
  3. Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease
  4. Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease
  5. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver
  6. Mutant PNPLA3 I148M protein as pharmacological target for liver disease
  7. Hepatic iron is the major determinant of serum ferritin in NAFLD patients
  8. Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease
  9. Editorial: new insights into the relationship between the intestine and non-alcoholic fatty liver-is “fatty gut” involved in disease progression?
  10. Fibronectin Type III Domain–Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
  11. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
  12. Hepcidin resistance in dysmetabolic iron overload
  13. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage
  14. Reply
  15. Reply
  16. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients
  17. Particulate matter phagocytosis induces tissue factor in differentiating macrophages
  18. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease
  19. The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.
  20. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance
  21. CDKN1A: A double-edged sword in fatty liver?
  22. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B
  23. PNPLA3 Ile148Met variant and hepatocellular carcinoma: A matter of fat
  24. I148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology
  25. Iron and the Adipocyte: Beware the Liver!
  26. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease
  27. Patatin-like phospholipase domain containing-3gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis
  28. Modulation of Iron Metabolism and Hepcidin Release by HFE Mutations in Chronic Hemodialysis Patients: Pathophysiological and Therapeutic Implications
  29. PNPLA3 I148M polymorphism and liver damage in obese children
  30. Patatin-like phospholipase domain-containing protein 3 genotype and hepatocellular carcinoma in chronic hepatitis C
  31. Reply
  32. Reply:
  33. Risk of severe liver disease in nonalcoholic fatty liver disease: Role of insulin resistance
  34. HFEmutations in nonalcoholic fatty liver disease
  35. Turning up the heat in the fat cell
  36. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance
  37. TNFα Promoter Polymorphisms